Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial
Authors' conclusion
This subgroup analysis confirms that semaglutide is effective in individuals with baseline BMI <35 and ≥35 kg/m2 , including in those with comorbidities.
Study context
- Population
- Adults without diabetes with BMI ≥30 kg/m², or BMI ≥27 kg/m² with ≥1 weight-related comorbidity; subgroups by baseline BMI <35 vs ≥35 kg/m² (no additional criteria, ≥1 comorbidity, prediabetes, prediabetes and high cardiovascular disease (CVD) risk)
- Comparison
- Once-weekly SC semaglutide 2.4 mg vs placebo, by baseline BMI <35 vs ≥35 kg/m²
Methodological detailsexploratory subgroup analysis
- Exploratory subgroup analysis
Primary result
As reported in the abstract
Mean change in body weight with semaglutide, by baseline BMI subgroup · baseline to week 68
Semaglutide, BMI <35 kg/m²
−16.2%
mean
Semaglutide, BMI ≥35 kg/m²
−14.0%
mean
Semaglutide, BMI <35 kg/m² vs Placebo: P < 0.0001 vs. placebo · Semaglutide, BMI ≥35 kg/m² vs Placebo: P < 0.0001 vs. placebo
Further findings
- Beneficial effects of semaglutide on cardiometabolic risk factors were consistent across all subgroups
Original publication
Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring). Published 6 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →